{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:24:35Z","timestamp":1792027475402,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803632"],"award-info":[{"award-number":["81803632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejps.2021.105814","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T23:29:20Z","timestamp":1616196560000},"page":"105814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions"],"prefix":"10.1016","volume":"162","author":[{"given":"Wenyan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-7162","authenticated-orcid":false,"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105814_bib0001","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1254\/jphs.CRJ06006X","article-title":"Organic anion transporter family: current knowledge","volume":"100","author":"Anzai","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2021.105814_bib0002","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bcp.14204","article-title":"Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin","volume":"86","author":"Bhagunde","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105814_bib0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2021.105814_bib0004","unstructured":"CDER, 2020. In vitro drug interaction studies - cytochrome p450 enzyme - and transporter-mediated drug interactions: guidance for industry. https:\/\/www.fda.gov\/media\/134582\/download."},{"key":"10.1016\/j.ejps.2021.105814_bib0005","unstructured":"CDER, 2020. Clinical drug interaction studies - cytochrome P450 enzyme- and transporter-mediated drug interactions: guidance for industry. https:\/\/www.fda.gov\/media\/134581\/download."},{"key":"10.1016\/j.ejps.2021.105814_bib0006","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/jac\/dkz101","article-title":"Role of transporters in the disposition of a novel \u03b2-lactamase inhibitor: relebactam (MK-7655)","volume":"74","author":"Chan","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2021.105814_bib0007","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2015.12.018","article-title":"Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation","volume":"47","author":"Dong","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2021.105814_bib0008","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2017.03.022","article-title":"Recent updates of carbapenem antibiotics","volume":"131","author":"EI-Gamal","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2021.105814_bib0009","unstructured":"EMA, 2012. Guideline on the investigation of drug interactions. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf."},{"key":"10.1016\/j.ejps.2021.105814_bib0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1128\/AAC.23.5.692","article-title":"Pharmacokinetics of sulbactam in humans","volume":"23","author":"Foulds","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2021.105814_bib0011","first-page":"345","article-title":"Treatment options for carbapenem-resistant gram-negative infections","volume":"115","author":"Fritzenwanker","year":"2018","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.ejps.2021.105814_bib0012","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/cpt.1360","article-title":"Clinical aspects of transporter-mediated drug-drug interactions","volume":"105","author":"Gessner","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2021.105814_bib0013","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/17425255.2010.506187","article-title":"Pharmacokinetic evaluation of piperacillin-tazobactam","volume":"6","author":"Hayashi","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.ejps.2021.105814_bib0014","first-page":"F122","article-title":"Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney","volume":"276","author":"Hosoyamada","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejps.2021.105814_bib0015","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.apsb.2019.02.005","article-title":"Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)","volume":"9","author":"Huo","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejps.2021.105814_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/ptr.6727","article-title":"Targeting renal OATs to develop renal protective agent from traditional Chinese medicines: protective effect of Apigenin against Imipenem-induced nephrotoxicity","author":"Huo","year":"2020","journal-title":"Phytother. Res."},{"key":"10.1016\/j.ejps.2021.105814_bib0018","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","article-title":"Renal drug transporters and drug interactions","volume":"56","author":"Ivanyuk","year":"2017","journal-title":"Clin. Pharmacokinet"},{"issue":"11","key":"10.1016\/j.ejps.2021.105814_bib0019","first-page":"1250","article-title":"Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function","volume":"47","author":"Koeppe","year":"1997","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.ejps.2021.105814_bib0020","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1128\/AAC.42.6.1433","article-title":"Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects","volume":"42","author":"Kozawa","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2021.105814_bib0021","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug-drug interactions: important determinants of drug disposition and effects","volume":"65","author":"K\u00f6nig","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2021.105814_bib0022","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1126\/science.352.6287.758","article-title":"Resistance fighters","volume":"352","author":"Kupferschmidt","year":"2016","journal-title":"Science"},{"issue":"Suppl 7","key":"10.1016\/j.ejps.2021.105814_bib0024","first-page":"S73","article-title":"Renal transporter-mediated drug-drug interactions: are they clinically relevant?","volume":"56","author":"Lepist","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105814_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41401-019-0283-z","article-title":"Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1\/3 and MRP2","volume":"41","author":"Liao","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2021.105814_bib0026","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-981-13-7647-4_5","article-title":"Transporter-mediated drug-drug interactions and their significance","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.ejps.2021.105814_bib0027","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1074\/jbc.272.10.6471","article-title":"Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney","volume":"272","author":"Lopez-Nieto","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2021.105814_bib0028","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The organic anion transporter (OAT) family: a systems biology perspective","volume":"95","author":"Martovetsky","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejps.2021.105814_bib0029","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-pharmtox-011112-140317","article-title":"Renal transporters in drug development","volume":"53","author":"Morrissey","year":"2013","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.ejps.2021.105814_bib0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/jac\/46.5.839","article-title":"Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis","volume":"46","author":"Nagashima","year":"2000","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ejps.2021.105814_bib0033","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2021.105814_bib0034","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1128\/AAC.01151-16","article-title":"Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A family","volume":"60","author":"Parvez","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2021.105814_bib0035","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","volume":"62","author":"Perry","year":"2002","journal-title":"Biapenem. Drugs"},{"key":"10.1016\/j.ejps.2021.105814_bib0036","unstructured":"PMDA, 2014. Drug interaction guideline for drug development and labeling recommendations. http:\/\/www.nihs.go.jp\/mss\/T140710-jimu.pdf."},{"key":"10.1016\/j.ejps.2021.105814_bib0037","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0378-4347(00)84540-5","article-title":"Determination of benzylpenicillin in plasma and urine by high-performance liquid chromatography","volume":"342","author":"Rumble","year":"1985","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.ejps.2021.105814_bib0038","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.medmal.2020.01.001","article-title":"Comparative review of imipenem\/cilastatin versus meropenem","volume":"50","author":"Salmon-Rousseau","year":"2020","journal-title":"Med. Mal. Infect."},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2021.105814_bib0039","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1469-0691.2007.01868.x","article-title":"Parenteral carbapenems","volume":"14","author":"Shah","year":"2008","journal-title":"Clin. Microbiol. Infec."},{"key":"10.1016\/j.ejps.2021.105814_bib0040","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/00498250600944326","article-title":"Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem","volume":"36","author":"Shibayama","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2021.105814_bib0041","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2133\/dmpk.22.41","article-title":"Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters","volume":"22","author":"Shibayama","year":"2007","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.105814_bib0042","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects","volume":"47","author":"Stocker","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"48","key":"10.1016\/j.ejps.2021.105814_bib0044","doi-asserted-by":"crossref","first-page":"30088","DOI":"10.1074\/jbc.272.48.30088","article-title":"Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney","volume":"272","author":"Sweet D","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2021.105814_bib0045","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105814_bib0046","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0002-9343(82)90084-5","article-title":"Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals","volume":"73","author":"Whitley","year":"1982","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejps.2021.105814_bib0047","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/dmd.112.049569","article-title":"Organic anion transporter 3 interacts selectively with lipophilic \u03b2-lactam antibiotics","volume":"41","author":"Wolman","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2021.105814_bib0049","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-981-13-7647-4_7","article-title":"Roles of renal drug transporter in drug disposition and renal toxicity","volume":"1141","author":"Yang","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejps.2021.105814_bib0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jac\/35.1.75","article-title":"Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by \u03b2-lactamases","volume":"35","author":"Yang","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2021.105814_bib0051","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1007\/s00216-019-01891-2","article-title":"Ultrahigh-throughput absolute quantitative analysis of linezolid in human plasma by direct analysis in real time mass spectrometry without chromatographic separation and its application to a pharmacokinetic study","volume":"411","author":"Yin","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejps.2021.105814_bib0052","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1734-1140(13)71026-0","article-title":"Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3","volume":"65","author":"Ye","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2021.105814_bib0053","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2012.06.004","article-title":"Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3","volume":"47","author":"Ye","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105814_bib0054","first-page":"252","article-title":"Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin","volume":"15","author":"Zhu","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2021.105814_bib0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.peptides.2012.01.007","article-title":"Organic anion transporters involved in the excretion of bestatin in the kidney","volume":"33","author":"Zhu","year":"2012","journal-title":"Peptides"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:29:01Z","timestamp":1777591741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":49,"alternative-id":["S0928098721001160"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105814","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105814"}}